Introduction
============

(--)-Morphine (**1**) is one of the oldest and most extensively used analgesics which led it, along with its congeners (--)-codeine (**2**) and (--)-thebaine (**3**), to garner significant attention from numerous organic chemists as targets for synthesis ([Fig. 1](#fig1){ref-type="fig"}).[@cit1] Extensive modifications to the naturally occurring opioids have also been investigated in endeavors to increase potency and *in vivo* efficacy and have led to the discovery of semi-synthetic opioids such as (--)-ketorfanol (**4**)[@cit2] and the extensively prescribed (--)-oxycodone (**5**).[@cit3] However, despite the medical importance of naturally occurring and semi-synthetic opioid agonists, undesired side effects such as addictive properties and the potential for fatal overdoses are enormous societal problems. Therefore, semi-synthetic opioid antagonists were developed to address these growing problems.[@cit4] Naltrexone (**6**) was first patented in 1967 ([@cit5]) and is currently an important treatment option for opioid abuse and alcohol dependence.[@cit4] The C-14 hydroxyl and *N*-cyclopropylmethyl substituent are essential structural features that are important for (--)-naltrexone\'s potency and antagonistic properties.[@cit4]

![Representative naturally occurring opioids (**1--3**) and semisynthetic opioid agonists (**4--5**) and an antagonist (**6**).](c8sc03748e-f1){#fig1}

The prevalent commercial routes to (--)-naltrexone (**6**) employ the natural product (--)-thebaine (**3**) as the starting material. A number of strategies have been developed for exchange of the *N*-methyl for an *N*-cyclopropylmethyl group.[@cit6]

Hudlicky has extensively investigated this step,[@cit7] including a particularly efficient alkylation and demethylation sequence of the thebaine derivative oripavine to give **9** ([Fig. 2](#fig2){ref-type="fig"}).[@cit7c] The dienol ether functionality present in (--)-thebaine allows for the straightforward introduction of the C-14 hydroxyl group by oxidative methods. For example, in Hudlicky\'s sequence, the dienol ether functionality in **9** was epoxidized followed by *in situ* oxirane ring opening to generate enone **10** followed by hydrogenation to give (--)-naltrexone ([Fig. 2](#fig2){ref-type="fig"}).[@cit8] Rice has also reported a semi-synthesis of the (+)-enantiomer of naltrexone. His synthesis proceeded through (+)-thebaine, which was prepared in five steps from the natural product (+)-sinomenine as an innovative starting material.[@cit9]

![Hudlicky\'s semi-synthesis of (--)-naltrexone.[@cit7c]](c8sc03748e-f2){#fig2}

(--)-Thebaine is currently isolated from opium poppies but is only a minor component of opium (0.3--1.5%), and poppy farming is problematic due to illicit drug activities.[@cit10] An alternative synthetic route that bypasses (--)-thebaine and starts with commercially available achiral precursors would provide novel entry to (--)-naltrexone. Moreover, starting from simple inputs should enable the investigation of a variety of analogs not accessible from more fully elaborated and densely functionalized morphinan natural products like (--)-thebaine.[@cit11]

Recently, we reported the synthesis of the unnatural enantiomer of the opioid agonist (+)-ketorfanol (**4**) ([Fig. 1](#fig1){ref-type="fig"}) using a Rh([i]{.smallcaps})-catalysed C--H alkenylation and torquoselective 6-π electrocyclization cascade as a key step in the sequence.[@cit12] Herein, we further apply this cascade approach to the synthesis of the considerably more complex opioid antagonist (--)-naltrexone (**6**) ([Scheme 1](#sch1){ref-type="fig"}). Imine **11** is efficiently prepared from achiral starting materials with catalytic asymmetric dihydroxylation used to introduce the stereogenic centers. Intramolecular Rh([i]{.smallcaps})-catalysed alkenylation to give azatriene **12** is followed by *in situ* torquoselective electrocyclization to set the desired stereochemistry in bicyclic hexahydroisoquinoline **13**, which is reduced to obtain **14** as a single diastereomer. Acid treatment provides the tetracyclic morphinan **15** by concomitant removal of the protecting groups, Grewe cyclization and redox neutral conversion of the diol to the desired keto group. The 4-methoxy-3,5-disilyloxy substitution pattern on the phenyl ring of **14** was designed to allow for incorporation of the required aromatic ring oxygen substitution pattern while simultaneously ensuring that Grewe cyclization occurs without the possibility of generating regiosomeric products (*vide infra*).[@cit1f] The pentacyclic ether **16** is then obtained from tetracyclic **15** by treatment with Br~2~ in AcOH according to methods developed for the synthesis of codeine.[@cit13]

![Approach to (--)-naltrexone from simple, achiral precursors.](c8sc03748e-s1){#sch1}

For intermediate **16**, installation of the hydroxyl group at C-14 would most efficiently be accomplished by dehydrogenation to an enone followed by C--H γ-hydroxylation. However, in syntheses of morphinan natural products such as morphine and codeine, researchers have found that for the efficient dehydrogenation of 6-keto derivatives to enones the nitrogen must be protected by an electron withdrawing carbamoyl or sulphonamide rather than an *N*-alkyl group as is present in **16**.[@cit1q],[@cit1u],[@cit14] Therefore, to enable dehydrogenation and γ-hydroxylation of **16** without the protection of the nitrogen, a Pd-mediated dehydrogenation method and Cu([ii]{.smallcaps})-catalysed O~2~-mediated allylic C--H oxidation conditions were developed. Alkene hydrogenation with concomitant reductive cleavage of both the triflate and the bromide in **18** gave **19**, which upon demethylation provided (--)-naltrexone in 17 steps for the longest linear sequence. Because the stereochemistry is set by asymmetric catalytic dihydroxylation, the same route could equally be employed to prepare the (+)-enantiomer of naltrexone, which has been reported to have antagonist activity toward Toll-like receptor 4.[@cit15]

Results and discussion
======================

The synthesis commenced with the preparation of imine **11** in seven steps from simple achiral starting materials ([Scheme 2](#sch2){ref-type="fig"}). Horner--Wadsworth--Emmons (HWE) reaction of aldehyde **21** and phosphonate **23** afforded **24** in 67% yield. Based upon a report by Takacs,[@cit16] we found that use of LiOH as the base in the presence of 4 Å molecular sieves minimized competitive self-condensation of aldehyde **21** and thus provided the most robust and reproducible HWE reaction conditions particularly on larger scales. Highly regio- and enantioselective dihydroxylation with AD-mix-β followed by protection of the diol as an acetonide gave **26** in high overall yield. The benzyl chloride **27**, which was coupled with alkyne **26**, was readily prepared in 75% overall yield from 4-*O*-methyl-3,5-dihydroxybenzoic acid, by silylation,[@cit17] LiAlH~4~ reduction to the benzyl alcohol,[@cit1af] and chlorination with thionyl chloride. For the coupling of benzyl chloride **27** and alkyne **26**, the Cu-free conditions developed by Buchwald for the Heck alkynylation of benzyl chlorides proved to be the most effective approach.[@cit18] Coupling product **28** was reliably obtained in good yield using Pd(OAc)~2~ as the precatalyst and X-Phos as the ligand. DIBAL reduction of the ester followed by Dess--Martin periodinane (DMP) oxidation of the resulting alcohol gave aldehyde **29** in 71% overall yield. Condensation with cyclopropylmethylamine then provided **11**, which was taken on to the next step without purification.

![Reactions and conditions: (a) (COCl)~2~ (1.16 equiv.), DMSO (2.2 equiv.), Et~3~N (5.0 equiv.), CH~2~Cl~2~, --78 → 23 °C; (b) P(OEt)~3~, neat, 120 °C; (c) LiOH·H~2~O (1.1 equiv.), MS 4 Å, THF, reflux; (d) K~2~OsO~4~·2H~2~O (1 mol%), (DHQD)~2~PHAL (5 mol%), K~3~Fe(CN)~6~ (3.00 equiv.), K~2~CO~3~ (3.00 equiv.), MeSO~2~NH~2~ (1.00 equiv.), tBuOH/H~2~O, 0 °C; (e) 2,2-dimethoxypropane (10 equiv.), TsOH·H~2~O (10 mol%), CH~2~Cl~2~, 0 °C; (f) Pd(OAc)~2~ (5 mol%), XPhos (15 mol%), Cs~2~CO~3~ (1.5 equiv.), dioxane, 65 °C; (g) DIBAL (4.0 equiv.), THF, --78 °C; (h) DMP (1.75 equiv.), pyridine (6.0 equiv.), CH~2~Cl~2~, 0 °C; (i) cyclopropylmethylamine (1.2 equiv.), MS 3 Å, PhMe, 23 °C.](c8sc03748e-s2){#sch2}

Next, imine **11** was treated with 5 mol% of \[RhCl(coe)~2~\]~2~ precatalyst using (pNMe~2~)PhPEt~2~ as the ligand with heating in toluene to initiate the Rh([i]{.smallcaps})-catalysed cascade sequence. This process proceeds by Rh([i]{.smallcaps})-catalysed C--H activation followed by intramolecular insertion of the alkyne to give azatriene **12**, which *in situ* undergoes rapid electrocyclization to provide 1,2-dihydropyridine **13** ([Scheme 3](#sch3){ref-type="fig"}). This cascade process not only forms the desired bicyclic ring system, but also proceeds with high torquoselectivity as enforced by the isopropylidene protected diol to provide the desired diastereomer.[@cit12] Without isolation, hexahydroisoquinoline **13** was reduced under mild conditions to give the octahydroisoquinoline **14** as a single stereoisomer in 66% overall yield from imine **11**.

![Rh([i]{.smallcaps}) C--H functionalization cascade. Condition and reagents: (a) \[RhCl(coe)~2~\]~2~ (5 mol%), (pNMe~2~)PhPEt~2~ (10 mol%), PhMe, 85 °C; (b) NaBH(OAc)~3~ (5.0 equiv.), AcOH, EtOH, 0 °C.](c8sc03748e-s3){#sch3}

Treatment of octahydroisoquinoline **14** with dilute H~3~PO~4~ and heat afforded morphinan **15** in 66% yield ([Scheme 4](#sch4){ref-type="fig"}). Acid treatment to provide morphinan **15** likely proceeds by removal of the silyl and acetonide protecting groups followed by *in situ* redox neutral conversion of the diol to the keto group *via* allylic alcohol ionization and a hydride shift to provide **30**, which then undergoes Grewe cyclization. Methods for α-bromination and subsequent nucleophilic displacement by an adjacent phenol as developed for the synthesis of codeine[@cit13] gave the dihydrobenzofuran **16** in good overall yield. Two equivalents of Br~2~ were needed because the first equivalent of Br~2~ was very rapidly consumed by bromination of the highly electron-rich aromatic ring. Bromine substitution did not pose a problem because we anticipated that it could be removed with a global reduction step planned for later in the sequence (*vide infra*). Prior to installation of the C-14 hydroxyl, the free phenol in **16** was converted to the triflate in **17**,[@cit17] which would also be removed in the reduction step.

![Synthesis of dehydrogenated enone **31** as the precursor to Installation of C-14. Conditions and reagents: (a) 55% H~3~PO~4~, 125 °C; (b) Br~2~ (2.0 equiv.), AcOH, 23 °C; NaOH~(aq)~, 23 °C; (c) Tf~2~O (3.3 equiv.), pyridine, 0 °C; (d) Pd(TFA)~2~ (1.4 equiv.), TFA, DMSO, 80 °C.](c8sc03748e-s4){#sch4}

C-14 C--H hydroxylation of triflate **17** first required dehydrogenation to enone **31** in order to activate this site for γ oxidation ([Scheme 4](#sch4){ref-type="fig"}). Direct dehydrogenation has been reported to proceed with low yield for basic opioids with *N*-alkyl amine substituents.[@cit14] To overcome this challenge in the synthesis of opioids, the amine is typically protected as a sulfonamide or carbamate,[@cit1q]^,au,^[@cit14] which then requires subsequent protecting group removal and installation of the *N*-alkyl group. Alternatively, more indirect, longer sequences have been developed to introduce this unsaturation.[@cit19] We instead chose to investigate contemporary ketone dehydrogenation approaches that have been reported to be compatible with amine functionality. We first evaluated the IBX-MPO system, but the conversion of **17** to enone **31** was not observed.[@cit20] Efficient, catalytic dehydrogenation methods utilizing \[Pd(allyl)~2~Cl\]~2~ with zinc amide bases have recently been reported,[@cit21] but only partial conversion to enone **31** along with some allylation at the α-position occurred. Dehydrogenation with Pd(TFA)~2~ in AcOH using O~2~ as an external oxidant resulted in significant *N*-dealkylation.[@cit22] This outcome is not surprising because Pd([ii]{.smallcaps}) catalysts under oxidizing conditions have been developed for the *N*-dealkylation of tertiary amines.[@cit7a],[@cit23] However, by addition of trifluoroacetic acid to protect the amine as the corresponding salt, along with DMSO as a coordinating solvent to stabilize Pd(TFA)~2~, complete conversion of ketone **17** was observed, with enone **31** isolated in 82% yield.

For the C-14 C--H hydroxylation of enone **31**, we looked for inspiration in prior semi-syntheses of oxycodone from morphine and codeine. Unfortunately, neither Co(OAc)~3~ in acetic acid as reported by Rice[@cit24] nor MnO~2~ in CHCl~3~ as reported by Sainsbury[@cit25] resulted in C-14 hydroxylation of **31**. We next investigated a method reported for the direct C-14 C--H hydroxylation of codeinone by metal-catalysed peroxidation with O~2~ followed by *in situ* reduction with sodium thiosulfate (entry 1, [Table 1](#tab1){ref-type="table"}).[@cit26] Disappointingly, no product was detected presumably because enone **31** is completely insoluble in the aqueous pH 8 buffer used as the solvent.[@cit27] This led us to extensively explore organic co-solvents in combination with different oxidation catalysts and reductants. A large number of different co-solvents were first investigated, including DMF, THF, EtOH, DMSO and CH~3~CN, but little to no product was detected. With pyridine as a 1 : 1 co-solvent with aqueous pH 8 buffer, enone **31** was highly soluble, and while some of the desired C--H hydroxylation product **18** was formed, extensive over-oxidation occurred as determined by LCMS (entry 2). However, by attenuating the basicity of the PBS buffer to pH 7, an improved yield of desired product **18** was obtained (entry 3). Under these conditions, CuSO~4~ proved to be a superior oxidation catalyst than KMnO~4~ (entry 4). Use of ketoglutaric acid instead of thiosulfate to reduce the peroxide intermediate was investigated for both KMnO~4~ (entry 5) and CuSO~4~ (entry 6). A significant improvement was observed for both catalysts with the highest yield obtained for CuSO~4~ (entry 6). Finally, varying the ratio of pyridine to PBS buffer resulted in vast differences in reaction rate. While the use of pyridine without any aqueous co-solvent resulted in a slower rate, reaction progress could be more easily monitored and therefore the reaction could be reliably terminated before significant over-oxidation had occurred (entry 7).

###### Optimization of γ-C--H hydroxylation of **31**

  ![](c8sc03748e-u1.jpg){#ugr1}                                                                        
  ------------------------------- --------- ------------------- --------------------------- ----- ---- ----
  1                               KMnO~4~   Na~2~S~2~O~3~       PBS pH 8                    42    49   0
  2                               KMnO~4~   Na~2~S~2~O~3~       PBS pH 8/pyridine (1 : 1)   42    0    11
  3                               KMnO~4~   Na~2~S~2~O~3~       PBS pH 7/pyridine (1 : 1)   42    11   17
  4                               CuSO~4~   Na~2~S~2~O~3~       PBS pH 7/pyridine (1 : 1)   5     5    31
  5                               KMnO~4~   Ketoglutaric acid   PBS pH 7/pyridine (1 : 1)   18    15   33
  6                               CuSO~4~   Ketoglutaric acid   PBS pH 7/pyridine (1 : 1)   1.5   0    55
  7                               CuSO~4~   Ketoglutaric acid   Pyridine                    48    8    59

^*a*^Catalysts were added as 5 mM stock solutions in deionized H~2~O.

^*b*^Reductants were added as a 150 mM stock solution in deionized H~2~O.

^*c*^All solvents were sparged with O~2~ prior to reaction.

^*d*^The reaction was stopped when the product was at maximum yield as determined by LCMS exact ion count.

^*e*^1,3,5-Trimethoxybenzene was used as a standard for NMR yields. Remaining percent balance corresponds to unidentified overoxidized or degraded product.

After γ-hydroxylation to afford **18**, we attempted to remove the aryl bromide and triflate as well as hydrogenate the enone to access **19** in a single step ([Scheme 5](#sch5){ref-type="fig"}). While formic acid with Pd(PPh~3~)~4~ only reductively cleaved the triflate and bromide, hydrogenation with H~2~ and Pd/C reduced the double bond and achieved hydrodebromination but without reductive cleavage of the triflate. However, Pearlman\'s catalyst (Pd(OH)~2~) under 1 atm of H~2~ resulted in the complete reduction of the double bond along with the reductive removal of both the bromide and the triflate to give **19** in nearly quantitative yield.[@cit28] For this reason, **19** was not purified but rather was directly submitted to final BBr~3~ mediated demethylation, affording (--)-naltrexone **6** in 67% yield over the two steps.

![Installation of C-14 hydroxylation and endgame synthesis to (--)-naltrexone (**6**). Conditions and reagents: (a) CuSO~4~ (2 mol%), ketoglutarate (4.5 equiv.), pyridine, 23 °C, O~2~; (b) Et~3~N (10 equiv.), Pd(OH)~2~ (20 wt%), EtOAc : MeOH = 1 : 3, H~2~, 23 °C; (c) BBr~3~ (5 equiv.), CH~2~Cl~2~, --40 → 0 °C.](c8sc03748e-s5){#sch5}

Conclusions
===========

We have developed a new approach for the synthesis of (--)-naltrexone in 17 linear steps. Starting with commercially available achiral substrates, a bicyclic hexahydroquinoline intermediate was accessed *via* a Rh([i]{.smallcaps})-catalyzed C--H alkenylation and torquoselective electrocyclization cascade. Grewe cyclization then provided the morphinan core with a concomitant hydride shift introducing the C-6 oxo functionality present in naltrexone. After formation of the dihydrobenzofuran, Pd-mediated dehydrogenation to the enone followed by allylic C--H oxidation using Cu([ii]{.smallcaps}) and O~2~ introduced the C-14 hydroxyl group. This new route for the asymmetric synthesis of (--)-naltrexone from simple, achiral precursors could provide a means to prepare morphinan derivatives that would be difficult to access through semi-synthesis from opioid natural products.
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